BioInvent International ABBOVNF 53 PS Ratio is 9.48 as of Jul. 01, 2026, which is 23% below its 10-year median of 12.24. GuruFocus rates BOVNF with a GF Score™ of 53/100 and a GF Value™ of $6.77. The stock has 4 warning signs investors should review. Among 934 Biotechnology companies, BioInvent International AB ranks better than 56.21% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, BioInvent International AB's share price is $3.2886.
BioInvent International AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.35. Hence, BioInvent International AB's PS Ratio for today is 9.48.
The historical rank and industry rank for BioInvent International AB's PS Ratio or its related term are showing as below:
BOVNF'
s PS Ratio Range Over the Past 10 Years
Min: 3.38 Med: 12.24 Max: 122.87
Current: 7.29
During the past 13 years, BioInvent International AB's highest PS Ratio was 122.87. The lowest was 3.38. And the median was 12.24.
BOVNF's PS Ratio is ranked better than 56.21% of 934
companies
in the Biotechnology industry
Industry Median: 9.515
vs BOVNF: 7.29
BioInvent International AB revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of BioInvent International AB was 258.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -13.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -4.60% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -11.30% per year.
During the past 13 years, BioInvent International AB's highest 3-Year average Revenue per Share Growth Rate was 72.00% per year. The lowest was -49.60% per year. And the median was -13.40% per year.
Back to Basics: PS Ratio
BioInvent International AB (OTCPK:BOVNF) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
BioInvent International AB PS Ratio Related Terms
BioInvent International AB PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BioInvent International AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioInvent International AB PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioInvent International AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where BioInvent International AB's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
BioInvent International AB's Share Price of today is $3.2886. BioInvent International AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.35.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
BioInvent International AB (BOVNF) has a PS Ratio of 9.48 as of Jul. 01, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on BioInvent International AB and its competitors. This is 23% below median its historical median of 12.24. Over the past decade, BioInvent International AB's PS Ratio has ranged from 3.38 to 122.87. According to the industry distribution chart, BioInvent International AB ranks #409 out of 934 companies in the Biotechnology industry, placing it in the top 43.8%.
Is BioInvent International AB's PS Ratio too high?
BioInvent International AB's current PS Ratio of 9.48 is 23% below median its 10-year median of 12.24. Over the past 10 years, this metric has ranged from a low of 3.38 to a high of 122.87. The Biotechnology industry median PS Ratio is 9.52. BioInvent International AB's value of 9.48 is 0.4% below this industry median. Based on the distribution chart, BioInvent International AB ranks #409 out of 934 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioInvent International AB has a GF Score™ of 53/100, reflecting its overall financial health beyond just this single metric.
How does BioInvent International AB's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioInvent International AB ranks #409 out of 934 companies for PS Ratio. This puts BioInvent International AB in the upper half of its industry. The industry median PS Ratio is 9.52. BioInvent International AB's value of 9.48 is 0.4% below this benchmark. Historically, BioInvent International AB's own PS Ratio has ranged from 3.38 to 122.87 over the past decade. While the company's 10-year median is 12.24 vs. the industry median of 9.52, BioInvent International AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.52, based on 934 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioInvent International AB's current PS Ratio of 9.48 is 0.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on BioInvent International AB and its competitors. For the Biotechnology industry, the median PS Ratio is 9.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioInvent International AB's current PS Ratio is 9.48, which is 23% below median its own 10-year median of 12.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioInvent International AB stock overvalued right now?
BioInvent International AB (BOVNF) has a current PS Ratio of 9.48. The stock's GF Value™ is $6.77, compared to a current price of $3.29 — trading 51.4% below its estimated fair value. The current PS Ratio is 9.48, which is 23% below median its 10-year median of 12.24 and 0.4% below the Biotechnology industry median of 9.52. BioInvent International AB's overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For BioInvent International AB (BOVNF), the current PS Ratio is 9.48 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioInvent International AB (BOVNF) Overvalued in 2026?
Based on GuruFocus' analysis, BioInvent International AB stock appears to be undervalued.
The current stock price of $3.29 is trading 51.4% below its estimated GF Value™ of $6.77.
Key valuation signals for BOVNF:
PS Ratio: 9.48 (23% below median its 10-year median of 12.24)
GF Value™: $6.77 vs. price of $3.29 (51.4% below fair value)
Industry Position: 0.4% below the Biotechnology median (#409 of 934)
No single metric tells the full story. See the BOVNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
53GF Score
Get the complete analysis for BOVNF
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOVNF has been successfully added to your 
